These findings generate novel insights into the role of CCL28/CCR10 signaling in pathological angiogenesis, inflammation, and delayed skin wound healing associated with T2DM and potentially may lead to novel therapeutic strategies for DFUs. Here, CCL28 is linked to type 2 diabetes mellitus.